Table 3.
Second-line treatment: Kaplan–Meier estimates for mOS
| Second-line treatment | ||||
|---|---|---|---|---|
| Number of patients |
N
81 |
% 100 |
mOS Months; 95 % CI |
Significance Log rank |
| CTX backbone | ||||
| Oxaliplatin | 37 | 46 | n.d | n.d. |
| Irinotecan | 40 | 49 | ||
| Fluoropyrimidin mono | 3 | 4 | ||
| No CTX | 1 | 1 | ||
| Targeted therapy | ||||
| Anti-VEGF | 26 | 32 | 26.4 (12–28.8) | p = 0.76 |
| Anti-EGFR | 21 | 26 | 14.4 (4.8–24) | |
| None | 34 | 42 | 16.8 (8.4–27.6) | |
| CTX combinations | ||||
| Oxaliplatin/anti-EGFR | 4 | 5 | n.d. | n.d. |
| Irinotecan/anti-EGFR | 17 | 21 | ||
| Oxaliplatin/anti-VEGF | 15 | 19 | ||
| Irinotecan/anti-VEGF | 10 | 12 | ||
| Oxaliplatin/none | 18 | 22 | ||
| Irinotecan/none | 13 | 16 | ||